Unfinished business

Roger Blevins, president and CEO of Xsira Pharmaceuticals Inc., is going back to his roots to develop a compound he knows well: adenosine.

"We had taken our founding technology, which was a lab assay from Duke, and automated and validated it and started generating revenues," he said. However, "we had always said we had no intention to become a technology company but instead wanted to use the technology to develop our own drugs."...